It is tempting to speculate that, since most tumours have dysregulated G1 cell cycle control, which may be exploited by targeting intra S and G2M checkpoints to selectively target a tumour vulnerability, ATR, CHK1 and WEE1 inhibitors may prove the most successful either as single agents or in combination. This evidence concerns the gene CHEK1 and neoplasm.